Abstract:The equilibrium between histone acetylation and deacetylation plays an important role in cancer initiation and progression. The histone deacetylases (HDACs) are a class of key regulators of gene expression that enzymatically remove an acetyl moiety from acetylated lysine ε-amino groups on histone tails. Therefore, HDAC inhibitors have recently emerged as a promising strategy for cancer therapy and several pan-HDAC inhibitors have globally been approved for clinical use. In the present study, we designed and synthesized a series of substituted indole-based hydroxamic acid derivatives that exhibited potent anti-proliferative activities in various tumor cell lines. Among the compounds tested, compound 4o, was found to be among the most potent in the inhibition of HDAC1 (half maximal inhibitory concentration, IC50 = 1.16 nM) and HDAC6 (IC50 = 2.30 nM). It also exhibited excellent in vitro anti-tumor proliferation activity. Additionally, compound 4o effectively increased the acetylation of histone H3 in a dose-dependent manner and inhibited cell proliferation by inducing cell cycle arrest and apoptosis. Moreover, compound 4o remarkably blocked colony formation in HCT116 cancer cells. Based on its favorable in vitro profile, compound 4o was further evaluated in an HCT116 xenograft mouse model, in which it demonstrated better in vivo efficacy than the clinically used HDAC inhibitor, suberanilohydroxamic acid. Interestingly, compound 4k was found to have a preference for the inhibition of HDAC6, with IC50 values of 115.20 and 5.29 nM against HDAC1 and HDAC6, respectively.

Development of N-hydroxybenzamide Derivatives with Indole-Containing Cap Group As Histone Deacetylases Inhibitors

Development of N-Hydroxycinnamamide-Based Histone Deacetylase Inhibitors with an Indole-Containing Cap Group

Design, Synthesis, and Preliminary Bioactivity Evaluation of N1‐hydroxyterephthalamide Derivatives with Indole Cap As Novel Histone Deacetylase Inhibitors

Development of N-Hydroxycinnamamide-Based Hdac Inhibitors with Improved Hdac Inhibitory Activity and in Vitro Antitumor Activity

Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors

Design, Synthesis and Biological Evaluation of Novel Isoindolinone Derivatives As Potent Histone Deacetylase Inhibitors.

Development of 3-Hydroxycinnamamide-based HDAC Inhibitors with Potent in Vitro and in Vivo Anti-Tumor Activity

Design, Synthesis and Bioactivity Evaluations of 8-Substituted-quinoline-2-carboxamide Derivatives As Novel Histone Deacetylase (HDAC) Inhibitors.

Design, Synthesis and Biological Evaluation of 4-Anilinothieno[2,3-d]pyrimidine-based Hydroxamic Acid Derivatives As Novel Histone Deacetylase Inhibitors.

Design, synthesis, and preliminary bioactivity evaluation of N-benzylpyrimidin-2-amine derivatives as novel histone deacetylase inhibitor.

Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.

Design, Synthesis and Preliminary Bioactivity Evaluations of Substituted Quinoline Hydroxamic Acid Derivatives As Novel Histone Deacetylase (hdac) Inhibitors

Novel N-hydroxybenzamide Histone Deacetylase Inhibitors As Potential Anti-Cancer Agents.

Design, Synthesis and Biological Evaluation of Isoquinoline-Based Derivatives As Novel Histone Deacetylase Inhibitors

Design, Synthesis and Biological Evaluation of Quinoline Derivatives As HDAC Class I Inhibitors.

Design, synthesis, and in vitro biological evaluation of novel HDAC inhibitors bearing C-1 phenyl substituted tetrahydroisoquinoline Cap moiety as anti-tumor therapeutic agents

Discovery of A Series of Hydroximic Acid Derivatives As Potent Histone Deacetylase Inhibitors

Novel N-hydroxybenzamide-based HDAC Inhibitors with Branched CAP Group.

Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities

Design, Synthesis, And Activity Of Hdac Inhibitors With A N-Formyl Hydroxylamine Head Group

Discovery of 1,2,4-Oxadiazole-containing Hydroxamic Acid Derivatives As Histone Deacetylase Inhibitors Potential Application in Cancer Therapy.